Table 2.
Outcome Metrics, Overall, and Select Subgroups for Prediction of Pathologic Complete Response
| n | n pCR | Accuracy (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|---|---|---|
| Overall | 144 | 54 | 88.9 (82.6–93.5) | 88.0 (75.7–95.5) | 89.4 (81.3–94.8) |
| HR + /HER2- | 36 | 7 | 88.9 (73.9–96.9) | 80.0 (28.4–99.5) | 90.3 (74.2–98.0) |
| HER2 + | 49 | 23 | 91.8 (80.4–97.7) | 91.3 (72.0–98.9) | 92.3 (74.9–99.1) |
| TNBC | 59 | 24 | 86.4 (75.0–94.0) | 86.4 (65.1–97.1) | 86.5 (71.2–95.5) |
| Anthracycline-containing regimens | 103 | 40 | 86.4 (78.2–92.4) | 88.2 (72.5–96.7) | 85.5 (75.0–92.8) |
| Anthracycline-free regimens | 41 | 14 | 95.1 (83.5–99.4) | 87.5 (61.7–98.4) | 100.0 (86.3–100) |